Spatz

What Spatz does

Spatz FGIA Inc. (operating as Spatz) is a privately held US medical device company founded in 2006 and headquartered in Fort Lauderdale, Florida. The company manufactures and commercializes a single core product — the Spatz3 Adjustable Gastric Balloon, a silicone balloon implanted endoscopically into the stomach and filled with sterile saline to induce satiety for non-surgical weight loss. Spatz3 is positioned as the world's first and only FDA-cleared adjustable gastric balloon, uniquely allowing both volume increase (to extend weight loss and avoid plateaus) and volume decrease (to manage early balloon intolerance), with an approved 12-month implantation duration versus 6 months for competing balloons. The device has been implanted in over 160,000 patients across more than 80 countries, with cumulative patient weight loss exceeding 3.9 million pounds.

The company monetizes through hardware sales of the balloon device to a global network of partner physician clinics, complemented by licensing/royalty arrangements with clinic partners and a dedicated physician portal ecosystem. Its go-to-market is channel-led: patients are routed to partner clinics via a 'Find A Clinic' website locator, while physicians are supported through a separate physician website and Doctors Portal. The company has pursued a multi-language digital expansion (English plus Spanish for Spain, Mexico, Argentina, Chile, Colombia, and Brazilian Portuguese) and an active content marketing and earned-media program across CBS, ABC, FOX, NBC, Google News, and Yahoo News to drive consumer demand into the clinic channel. Spatz3 holds FDA, CE, TGA, and ANVISA regulatory clearances. The organization remains small (1–10 employees), founder/privately owned with no disclosed institutional capital, and operates with no published revenue, pricing, or product pipeline beyond the Spatz3 device.

Name

Spatz

Legal name

Spatz FGIA Inc.

Website

https://spatzmedical.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Spatz manufactures the Spatz3, the world's only FDA-cleared adjustable gastric balloon for non-surgical weight loss. It sells the device through a network of physician clinics across more than 80 countries, serving adults with obesity seeking reversible bariatric intervention.

Ownership category

akta.pro rank

Headquarters

HQ city

Great Neck

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Gastric Balloon Device Sales: Spatz sells its Spatz3 Adjustable Gastric Balloon to physician clinics and healthcare providers. The device is implanted during an endoscopic procedure at participating clinics. Revenue is generated from the sale of the balloon device to partner clinics.
2. Physician/Clinic Network: Spatz operates a partner clinic network across 80+ countries. Clinics pay to access the Spatz3 balloon technology and receive physician support through dedicated portals. The company provides clinical resources, support materials, and procedure guidance.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Spatz manufactures and distributes the Spatz3 Adjustable Gastric Balloon, a silicone saline-filled intragastric balloon implanted endoscopically for non-surgical weight loss. The device is the world's first and only adjustable gastric balloon, allowing volume modification (both up and down) after implantation, and is approved to remain in the stomach for up to 12 months. The balloon is sold to physician clinics and bariatric specialists across 80+ countries.

Product overview

Spatz offers a single core product—the Spatz3 Adjustable Gastric Balloon. The Spatz3 is the world's first and only adjustable gastric balloon system, designed as a non-surgical, non-invasive weight loss solution. Unlike static gastric balloons, the Spatz3 can be adjusted in volume (both up and down) after implantation to optimize patient comfort and maintain weight loss momentum throughout the treatment period. The device is approved to remain in the stomach for 12 months—twice as long as competing products outside the US—allowing patients extended time to adopt healthier eating habits. The company also provides a companion ecosystem including a Doctors Portal and Physician Website for healthcare providers, along with patient-facing resources such as dietary guides, BMI calculators, success stories, and multi-language content (English, Spanish, Portuguese, Colombian Spanish, Chilean Spanish, Argentine Spanish, Brazilian Portuguese).

Differentiator

Problem solved

Functional benefit

Products and services

• Spatz3 Adjustable Gastric Balloon

Quantifiable outcome

• Patients can lose up to 34.7% of their total body weight
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Boston Scientific: Boston Scientific is a large diversified medical device company that acquired Apollo Endosurgery (Orbera). It is a broad incumbent in the same bariatric/endoscopy space and competes with Spatz for physician mindshare, contracts, and clinic relationships.
• Medtronic: Medtronic is a diversified medical device incumbent that participates in bariatrics and endoscopy. It is relevant as a broad incumbent whose installed base, R&D scale, and clinical relationships can influence the bariatric device market in which Spatz competes.
• Novo Nordisk: Novo Nordisk markets Wegovy and Ozempic (semaglutide), the highest-profile GLP-1 drugs for obesity and diabetes. As with Eli Lilly, Novo Nordisk's pharmacotherapy is the most significant structural headwind to demand for endoscopic weight loss balloons like Spatz3.
• Johnson & Johnson (Ethicon): Ethicon, J&J's surgical device arm, is a leading player in bariatric and metabolic surgery. It represents the dominant surgical incumbent that Spatz3 is positioned against for the non-surgical segment of the same patient population.
• Eli Lilly: Eli Lilly markets Mounjaro and Zepbound (tirzepatide), the leading GLP-1 pharmacotherapies for obesity. While not a device company, Lilly is the most important indirect competitor to Spatz, as its drugs are reshaping the entire non-surgical obesity treatment landscape.

Emerging players

• Standard Bariatrics: Standard Bariatrics develops surgical bariatric devices (e.g., the Titan SGS stapler). While more focused on surgical bariatrics, it is a relevant adjacent player whose progress shapes the competitive landscape Spatz3 operates in for obese patients seeking intervention.
• EndoSphere: EndoSphere is an emerging medical device company developing non-surgical, endoscopic obesity therapies. It represents a potential future entrant into the same endoluminal space Spatz3 occupies.

Direct peers

• Apollo Endosurgery (Orbera): Apollo Endosurgery, now part of Boston Scientific, markets the Orbera Intragastric Balloon System, the most widely implanted 6-month endoscopic balloon globally. It is a head-to-head competitor to Spatz3 in physician offices and bariatric clinics.
• ReShape Lifesciences: ReShape markets the ReShape Vest System and has historically offered intragastric balloon products. It is a direct competitor in the non-surgical obesity device category, addressing similar patients and clinics.
• Allurion Technologies: Allurion makes the Elipse swallowable gastric balloon, the most prominent non-endoscopic, non-surgical weight loss balloon. It is the closest direct competitor to Spatz3 in the intragastric balloon category, addressing the same patient population with a different delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/spatz3balloon
• YouTubeyoutube.com/channel/UCy96xHV1-6Mnk51xxBWcvJQ
• Facebookfacebook.com/SpatzAdjustableGastricBalloon
• LinkedInlinkedin.com/company/spatz-adjustable-balloon
• Instagraminstagram.com/spatzadjustableballoon

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spatz